000086367 001__ 86367
000086367 005__ 20200716101557.0
000086367 0247_ $$2doi$$a10.3390/cancers11071012
000086367 0248_ $$2sideral$$a115028
000086367 037__ $$aART-2019-115028
000086367 041__ $$aeng
000086367 100__ $$aRodrigo, Alberto
000086367 245__ $$aThermal liquid biopsy (Tlb): A predictive score derived from serum thermograms as a clinical tool for screening lung cancer patients
000086367 260__ $$c2019
000086367 5060_ $$aAccess copy available to the general public$$fUnrestricted
000086367 5203_ $$aRisk population screening programs are instrumental for advancing cancer management and reducing economic costs of therapeutic interventions and the burden of the disease, as well as increasing the survival rate and improving the quality of life for cancer patients. Lung cancer, with high incidence and mortality rates, is not excluded from this situation. The success of screening programs relies on many factors, with some of them being the appropriate definition of the risk population and the implementation of detection techniques with an optimal discrimination power and strong patient adherence. Liquid biopsy based on serum or plasma detection of circulating tumor cells or DNA/RNA is increasingly employed nowadays, but certain limitations constrain its wide application. In this work, we present a new implementation of thermal liquid biopsy (TLB) for lung cancer patients. TLB provides a prediction score based on the ability to detect plasma/serum proteome alterations through calorimetric thermograms that strongly correlates with the presence of lung cancer disease (91% accuracy rate, 90% sensitivity, 92% specificity, diagnostic odds ratio 104). TLB is a quick, minimally-invasive, low-risk technique that can be applied in clinical practice for evidencing lung cancer, and it can be used in screening and monitoring actions.
000086367 536__ $$9info:eu-repo/grantAgreement/ES/DGA/E25-17R$$9info:eu-repo/grantAgreement/ES/DGA/E45-17R$$9info:eu-repo/grantAgreement/ES/FIS/PI15-00663$$9info:eu-repo/grantAgreement/ES/ISCIII/CPII13-00017$$9info:eu-repo/grantAgreement/ES/ISCIII-FIS/PI17-01109$$9info:eu-repo/grantAgreement/ES/ISCIII-FIS/PI18-00349$$9info:eu-repo/grantAgreement/ES/MINECO/BFU2016-78232-P
000086367 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000086367 590__ $$a6.126$$b2019
000086367 591__ $$aONCOLOGY$$b37 / 244 = 0.152$$c2019$$dQ1$$eT1
000086367 592__ $$a1.938$$b2019
000086367 593__ $$aOncology$$c2019$$dQ1
000086367 593__ $$aCancer Research$$c2019$$dQ1
000086367 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000086367 700__ $$0(orcid)0000-0003-0853-2880$$aOjeda, Jorge L.$$uUniversidad de Zaragoza
000086367 700__ $$0(orcid)0000-0002-1232-6310$$aVega, Sonia
000086367 700__ $$aSanchez-Gracia, Óscar
000086367 700__ $$0(orcid)0000-0001-5932-2889$$aLanas, Ángel$$uUniversidad de Zaragoza
000086367 700__ $$aIsla, Dolores
000086367 700__ $$0(orcid)0000-0001-5702-4538$$aVelazquez-Campoy, Adrián$$uUniversidad de Zaragoza
000086367 700__ $$0(orcid)0000-0001-5664-1729$$aAbian, Olga$$uUniversidad de Zaragoza
000086367 7102_ $$12007$$2265$$aUniversidad de Zaragoza$$bDpto. Métodos Estadísticos$$cÁrea Estadís. Investig. Opera.
000086367 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000086367 7102_ $$11002$$2060$$aUniversidad de Zaragoza$$bDpto. Bioq.Biolog.Mol. Celular$$cÁrea Bioquímica y Biolog.Mole.
000086367 773__ $$g11, 7 (2019), 1012 [20 pp.]$$pCancers$$tCancers$$x2072-6694
000086367 8564_ $$s2243274$$uhttps://zaguan.unizar.es/record/86367/files/texto_completo.pdf$$yVersión publicada
000086367 8564_ $$s95234$$uhttps://zaguan.unizar.es/record/86367/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000086367 909CO $$ooai:zaguan.unizar.es:86367$$particulos$$pdriver
000086367 951__ $$a2020-07-16-09:50:37
000086367 980__ $$aARTICLE